Q3 Loss Widens to $45.5M as Lyell Burns Cash Ahead of 2027 Pivotal Data
LYEL has more than doubled off its 52-week low of $7.195 on elevated volume (7.0× avg).
Summary
Lyell's Q3 net loss widened to $45.5M from $38.8M a year earlier, and the adjusted loss grew to $41.3M from $29.1M, driven by heavier clinical-trial spending and lower interest income. Cash and marketable securities fell to $194.0M at September 30 from $247.2M at year-end 2025. Management says that balance plus the $80.0M private placement priced this afternoon at $10.77 a share funds operations into 2028 — the placement was the reason for today's capital raise, and the runway statement is the payoff. The near-term execution item is PiNACLE enrollment, expected to finish by year-end, with pivotal data and a BLA submission targeted for the second half of 2027. Until then the story is burn rate versus that runway, and the widening loss is the number that matters.
At the time of this announcement, LYEL was trading at $15.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $378.1M. The 52-week trading range was $7.20 to $45.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.